HC Wainwright & Co. maintains Bicara Therapeutics at Buy, lowers price target to $36 from $42
HC Wainwright & Co. kept Bicara Therapeutics' rating at Buy but reduced its price target to $36 from $42, a 14.3% decrease. The new target suggests a 253.6% upside from the Nov 10 close of $10.18. Recent analyst price targets for the company range from $8 to $43.
How this was made
The 30-second read
Why it matters
The price‑target reduction may trigger short‑term selling but does not reflect a fundamental change in the company's pipeline.
Market read
Target cut is a modest catalyst for BICR, likely causing limited price movement.
What to watch
Potential pipeline milestones or partnership news not yet reflected in the target.
Background
Analyst coverage updates are common for micro‑cap biotech firms.
Market effects
Biotech sector may see modest target revisions across peers.
US biotech investors may adjust exposure.
Limited to investors tracking small‑cap biotech stocks.
Counterpoint
The target cut could be an overreaction; upcoming data may support upside.
Key entities
- analystHC Wainwright & Co.
Equity research firm providing the target revision.
- companyBicara Therapeutics
Biotech company focused on rare disease therapeutics.
